论文部分内容阅读
目的:对比分析国产伊马替尼(商品名:格尼可)和原研伊马替尼(格列卫)用于治疗慢性髓性白血病慢性期(CML-CP)患者的临床疗效与用药安全性差异。方法:回顾性分析42例接受格尼可治疗和83例接受格列卫治疗的CML-CP患者的临床资料,比较分析2组患者在3个月、6个月及12个月获得最佳疗效发生率的差异,对比2组患者发生血液学及非血液学不良反应发生率的差异。结果:2组患者3个月、6个月及12个月的最佳疗效发生率无统计学差异,不良反应发生率无统计学差异。结论:根据本次收集的临床资料分析结果,格尼可和格列卫治疗CML-CP患者的临床疗效相仿,患者对用药期间出现的不良反应均有良好的耐受性,显示出良好的用药安全性。
OBJECTIVE: To compare and analyze the clinical efficacy and safety of domestic imatinib (trade name: Gnostic) and original imatinib (Gleevec) in the treatment of chronic myeloid leukemia (CML-CP) patients difference. Methods: The clinical data of 42 CML-CP patients treated with Genipin and 83 patients treated with Gleevec were retrospectively analyzed. The best effect was obtained at 3, 6 and 12 months in two groups The difference between the incidence of hematological and non-hematological adverse reactions in two groups were compared. Results: There was no significant difference in the best curative effect between the two groups at 3 months, 6 months and 12 months. The incidence of adverse reactions was not statistically different. Conclusion: Based on the clinical data collected in this study, the clinical efficacy of Gurnee and Gleevec in patients with CML-CP was similar. The patients were well tolerated with adverse reactions during the medication and showed good medication safety.